TP53 in MDS and AML: Biological and clinical advances

Yeqian Zhao; Weihao Chen; Jing Yu; Shanshan Pei; Qiang Zhang; Jimin Shi; He Huang; Yanmin Zhao

doi:10.1016/j.canlet.2024.216767

TP53 in MDS and AML: Biological and clinical advances

Cancer Lett. 2024 Apr 28:588:216767. doi: 10.1016/j.canlet.2024.216767. Epub 2024 Feb 27.

Authors

Yeqian Zhao¹, Weihao Chen², Jing Yu³, Shanshan Pei¹, Qiang Zhang⁴, Jimin Shi¹, He Huang⁵, Yanmin Zhao⁶

Affiliations

¹ Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, 311121, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
² Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
³ Zhejiang University School of Medicine, Hangzhou, China.
⁴ Zhejiang Jianfeng Group Co., Ltd., China.
⁵ Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, 311121, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. Electronic address: huanghe@zju.edu.cn.
⁶ Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, 311121, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. Electronic address: yanminzhao@zju.edu.cn.

PMID: 38417666
DOI: 10.1016/j.canlet.2024.216767

Abstract

Recently, the WHO-5 and the ICC 2022 criteria have emphasized poor prognosis in AML/MDS patients with multi-hit TP53 mutations, whereas mutated TP53 plays a critical role in tumorigenesis, drawing substantial interest in exploring its biological behaviors. Diverse characteristics of TP53 mutations, including types, VAF, CNVs, allelic status, karyotypes, and concurrent mutations have been extensively studied. Novel potential targets and comprehensive treatment strategies nowadays are under swift development, owing to great advances in technology. However, accurately predicting prognosis of patients with TP53-mutated myeloid neoplasms remains challenging. And there is still a lack of effective treatment for those patients.

Keywords: Malignant progression; Multi-hit; Prognosis; TP53 mutations; Treatment; VAF.

Publication types

Review

MeSH terms

Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Mutation
Myelodysplastic Syndromes* / drug therapy
Myelodysplastic Syndromes* / genetics
Prognosis
Treatment Outcome
Tumor Suppressor Protein p53 / genetics

Substances

Tumor Suppressor Protein p53
TP53 protein, human